drugset
drugset / Trial / NCT02079324

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer

NCT02079324 ↗

Phase 1 Completed 12 enrolled Genexine, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to evaluate MTD, Safety and efficacy of GX-051 after intratumoral injection in head and neck cancer patience.

Timeline

Start
2014-03
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-051 Unknown — Other

Indications

head and neck cancer